Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase 2 Completed 52 enrolled Fudan University

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

Timeline

Start: 2017-05-04
Primary completion: 2020-12-31
Completion: 2021-12-31

Publications

Hu Z, Sun S, Zhao X, Yu H, Wu X, Wang J, Chang J, Wang H. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study. Oncologist. 2022 Apr 5;27(4):253-e312. doi: 10.1093/oncolo/oyab078.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DDP	Unknown	60 mg/m2	—
Subject	Endostar	Protein / enzyme biologic	15 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	60 mg/m2	—

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Summary

Timeline

Publications

Drugs

Indications